All revved up and ready to roll, Roche is handed the keys to a multibillion-dollar hemophilia market
Roche has a green light to greatly expand its sales effort behind Hemlibra, the landmark hemophilia drug that is making marketing life miserable at Shire …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
